Ontem, aproveitando uma viagem de ida e volta a Bragança iniciei a escuta do livro "The Coming Wave" de Mustafa Suleyman e Michael Bhaskar.
A certa altura, já no regresso fixei este trecho tão ao jeito de Mongo:
“The field of systems biology aims to understand the “larger picture” of a cell, tissue, or organism by using bioinformatics and computational biology to see how the organism works holistically; such efforts could be the foundation for a new era of personalized medicine. Before long the idea of being treated in a generic way will seem positively medieval; everything, from the kind of care we receive to the medicines we are offered, will be precisely tailored to our DNA and specific biomarkers. Eventually, it might be possible to reconfigure ourselves to enhance our immune responses. That, in turn, might open the door to even more ambitious experimentation like longevity and regenerative technologies, already a burgeoning area of research.”
Ao ouvir isto pensei logo no que pode tornar obsoleta a indústria farmacêutica tal como a conhecemos. E foi então que a imagem de Roger Martin, "For me, the metaphor for competitive advantage is a long row of rooms. In this conception, every company, at any given point in time, exists in a room of its own making", publicada ontem no blogue me assaltou. Quando aqui escrevo sobre a importância do investimento directo estrangeiro, estou na verdade a abordar a possibilidade de capital intelectual vindo de fora permitir unidades de negócio que dão saltos na sequência da "row of rooms"
